Background: Catheter ablation is an important rhythm control therapy in patients
| INTRODUC TI ON
Atrial Fibrillation (AF) and heart failure (HF) are two of the most common cardiovascular diseases. They both reduce quality of life and longevity, particularly when they accompany one another.
1,2 AF is independently associated with worse left ventricular systolic function and worse quality of life in patients with HF. [3] [4] [5] Furthermore, the presence of HF complicates treatment for AF, as several antiarrhythmic drugs are contraindicated because of the potential for harm in HF. Yet, the remaining guideline-advocated medical therapies, including dofetilide and amiodarone, suffer from suboptimal effectiveness and still have potential for harm. Drug toxicity is likely partly attributable for the failure of a "rhythm control" strategy to prove superior to rate-only control in AF patients with or without HF. 6, 7 Therefore, catheter ablation represents an appealing approach to the management of AF in these patients. [8] [9] [10] [11] [12] [13] .
Catheter ablation of AF is currently recommended for patients with symptomatic AF refractory to antiarrhythmic therapy. 14 It has proven to be an effective therapy in patients with HF, 15 resulting in improved freedom from AF, functional status and left ventricular function. [11] [12] [13] In the recently published randomized controlled trial Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF), AF ablation in patients with systolic HF led to statistically significant reductions in hospitalization and mortality. 16 It is well appreciated that the etiology of cardiomyopathy and differences in underlying substrate influence outcomes in both catheter ablation of ventricular tachycardia and cardiac resynchronization therapy. 17, 18 However, few studies have assessed the impact of HF etiology on outcomes of catheter ablation for concomitant AF. Accordingly, we sought to compare outcomes of AF ablation in patients with cardiomyopathy that was ischemic in origin, vs those with nonischemic cardiomyopathy. We hypothesized that patients with nonischemic cardiomyopathy may experience worse outcomes following AF ablation compared with patients with ischemic cardiomyopathy, because of a propensity for more extensive atrial myopathy.
| ME THODS
We conducted a retrospective observational cohort study within Patients with an implanted device received routine quarterly device interrogation including assessment for arrhythmia recurrence. 22 
| Statistical methods
Baseline and ablation characteristics were described using counts and percentages (categorical) or mean and standard deviation (continuous). Univariate comparisons of baseline and ablation characteristics were made using Chi-squared or Fisher's exact test for categorical variables and ANOVA for continuous variables as ap-
propriate. Changes in NYHA classification between baseline and the latest follow-up were analyzed using Wilcoxon signed rank test within each HF etiology group; changes were compared between the groups using Wilcoxon rank-sum test.
Comparisons of in-hospital and 12-month outcomes between HF etiology groups were performed using Chi-square tests. ). There were important differences in baseline characteristics between the two groups, including age (mean 69 for ischemic vs 64 for nonischemic, P = .002), gender (female 17%
for ischemic vs 36% for nonischemic, P = .004), and mean leftventricular ejection fraction (LVEF, 42% for ischemic vs 47% for nonischemic, P = .0007, Table 1 ). At baseline, there were no major differences in medical therapy between the two groups-patients not on antiarrhythmic therapy comprised 40% of the ischemic group and 35% of the nonischemic group (P = .28). Ablation procedure characteristics are shown in Table S1 and were roughly balanced between ischemic and nonischemic patients, including mean procedure times (259 minutes for ischemic vs 243 for nonischemic, P = .13), mean ablation time (58 minutes for ischemic, 56
for nonischemic, P = .6), and mean fluoroscopy time (51 minutes for ischemic vs 54 for nonischemic, P = .44). The most common adjunctive ablation, beyond PVI, was a left atrial roof line in both groups (40% for ischemic vs 41% of nonischemic, P = .92).
| Symptoms and quality of life
Symptom status at baseline and at follow-up are shown by NYHA class ( Figure 1 ) and modified MAFSI scores ( Figure 2 ). Nine patients were lost to follow-up. Following catheter ablation there were significant improvements in NYHA classification in both ischemic and nonischemic patients (P < .002 for change in scores for each). The proportion of patients with NYHA class III/IV symptoms decreased from 28% to 11% in the ischemic group (60% reduction) and 24% to 6% (75% reduction) in the nonischemic group.
However, changes in NYHA class were not different between ischemic and nonischemic patients (P interaction = .95). Modified MAFSI scores demonstrated significant improvement in symptom frequency ( Figure 2A ) while there were mixed trends for symptom severity ( Figure 2B ).
| Maintenance of sinus rhythm
Unadjusted clinical outcomes are shown in Table 2 . Overall, freedom from recurrent atrial arrhythmia was 76.8% at 12-months 
| Safety outcomes
In-hospital, periprocedural adverse events were uncommon overall, and low numbers precluded meaningful comparison between heart failure etiology groups. Specifically, acute decompensated HF only occurred in 11 patients, including 4.3% (n = 3/70) in those with ischemic cardiomyopathy vs 4.7% (n = 8/172) in those with nonischemic cardiomyopathy (P = 1.0). CI 0.43-0.87, P = .007). 16 Fewer patients receiving catheter ablation died during follow-up than medical therapy (HR 0.49, 95% CI 0.29-0.84, P = .009). 16 There was also a statistically nonsignificant trend toward improved clinical outcomes in patients in the CABANA trial with HF. 26 The result of CABANA, bolstered by other smaller ran- demonstrated that atrial fibrosis assessed using delayed gadolinium enhanced MRI is predictive of AF recurrence following ablation. 30 However, the 329 patient DECAAF study included a relatively few patients with congestive heart failure (n = 15) and coronary artery disease (n = 26) and found no statistical association between either factor and atrial fibrosis. 30 Importantly, we did not observe differences in outcomes between patients with ischemic cardiomyopathy vs those with nonischemic cardiomyopathy. A systematic review has shown greater improvement in ventricular function in cohorts with less ischemic disease undergoing catheter ablation for AF. 24 This finding was consistent in a recent, smaller cohort (n = 100) in which improved AF control was observed in patients with idiopathic cardiomyopathy undergoing ablation, compared to patients with known causes of structural heart disease. 31 Similar to our study findings, there F I G U R E 1 Change in NYHA class distribution from baseline to last followup after ablation, stratified by heart failure etiology. NYHA = New York Heart Association functional classification with class I = no limitation in normal activity, class II = mild symptoms only in normal activity, class III = marked symptoms during daily activities but asymptomatic at rest, and class IV = severe limitations with symptoms at rest was no difference in outcomes between patients with ischemic and nonischemic cardiomyopathy in CASTLE-AF. 27 It is unclear whether differential rates of recurrence and response among dis- The improvements in symptom frequency and functional status
| D ISCUSS I ON
were not different in patients with ischemic and nonischemic HF.
There are several possible explanations for the similar effectiveness observed in both ischemic and nonischemic HF patients. First, it is possible that AF ablation is equally durable in patients with ischemic and nonischemic cardiomyopathy despite differences in the underlying substrate or trigger density. It is also possible that short-term and immediate-term follow-up is similar, but with longer follow-up and more opportunity for substrate progression, differences would have 34 Patients with no LGE on MRI had greater LVEF improvement (10.7%, P = .0069) at 6 month follow-up. 34 Patients with less severe left ventricular dysfunction (LVEF 25%-35%) received more benefit from AF ablation than those with severe LV dysfunction (LVEF < 25%) in CASTLE-AF. 16 Detailed analysis of the HF population in the CABANA trial have not yet been published, but will hopefully provide additional insights.
| Limitations
This is a single-center, retrospective, observational study, which may limit generalizability. Furthermore, the diagnosis of heart failure with preserved ejection fraction was made clinically, and formal diagnostic criteria for this entity vary even in the context of carefully conducted clinical trials. However, our results in the overall HF cohort parallel those seen in other published reports. Another limitation is that the procedures represent a relatively homogenous approach to pulmonary vein isolation, and did not include cryoablation. Follow-up for recurrence with ambulatory monitoring (eg Holter monitor) was done based on clinical and symptom status rather than routine, as these procedures were performed for the primary indication of symptom relief. Asymptomatic patients did not undergo a routine monitoring outside of routine ECG follow-up unless they had an implanted device. Furthermore, the study period predates important advances in AF ablation, including contact force-sensing catheters, rotor mapping, and high-density electroanatomic mapping systems. 
TA B L E 2 Unadjusted outcomes by cardiomyopathy type

F I G U R E 3
Kaplan-Meier curve of arrhythmia-free survival to 12 months according to heart failure etiology, with a 3-month blanking period. AF recurrence was defined by electrocardiographic recurrence. Error bars represent 95% confidence limits However, it is not likely that these technical improvements would expect to impact one etiology of HF more than the other. Finally, despite the use of extensive multivariable adjustment, we cannot exclude the presence of unmeasured or residual confounding that might have impacted the results.
| CON CLUS IONS
Consistent with prior experience, catheter ablation for AF in patients with concomitant HF is associated with substantial improvement in symptoms, functional status, and freedom from recurrent atrial arrhythmia. While the underlying myopathic processes may be different in patients with ischemic and nonischemic HF, we found no significant differences in outcomes according to HF etiology following catheter ablation of AF. Unlike other electrophysiologic interventions, patients with ischemic and nonischemic cardiomyopathy appear to derive a similar magnitude of benefit following AF ablation. Further investigations are needed to determine which subgroups of patients with concomitant AF and HF are most likely to benefit from catheter ablation.
